<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752216</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV239B</org_study_id>
    <secondary_id>2018-002274-44</secondary_id>
    <nct_id>NCT03752216</nct_id>
  </id_info>
  <brief_title>NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.</brief_title>
  <acronym>NiQoLe</acronym>
  <official_title>Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal, national, open, multi-centre phase IV study which will recruit up to
      141 patients with ovarian cancer in late relapse treated with niraparib according to the
      labelling In France.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of NiQoLe is to evaluate tolerability of Niraparib and the management by the
      physicians of the side-effects in real life in France. The study will also generate data on
      longitudinal follow up of closed symptoms and side effects reported by the patients
      especially with the NCI PRO (Patient-Reported Outcome)-CTCAE system. Specific oncogeriatric
      data will be collected among on a subgroup of elderly patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities inducing dose modifications of Niraparib between the start to the cycle 3 (interruption, discontinuation and dose reduction).</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate treatment toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported fatigue by patient by FACT-F questionnaire (Functional Assessment of Cancer Therapy General - Fatigue)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Functional Assessment of Cancer Therapy General Fatigue questionnaire (score range from 0 to 52 - Higher scores represent better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported symptoms and side effects with the NCI PRO-CTCAE</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Self-reported symptoms and side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons of the dose modification of Niraparib</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Reasons of the dose modification of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health-related quality of life by FACT-G questionnaire (Functional Assessment of Cancer Therapy General)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Functional Assessment of Cancer Therapy General questionnaire (score range from 0 [worse outcome] to 108 [better outcome])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain related to the treatment by Visual Analogic Scale (VAS)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Score range from 0 [worse outcome] to 10 [better outcome])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of interest (HTA, anemia, thrombocytopenia)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Side effects of interest (HTA, anemia, thrombocytopenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Niraparib treatment</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>From the start of Niraparib until progression or unacceptable toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent line of anti-cancer therapy</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>From the stop of Niraparib to the first subsequent line of anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial cognitive functions by FACT-cog (Functional Assessment of Cancer Therapy - Cognitive Function) questionnaire</measure>
    <time_frame>At the inclusion visit</time_frame>
    <description>FACT-cog questionnaire (score range from 0 to 132 - Higher scores represent better functioning)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Niraparib before Niraparib administration</measure>
    <time_frame>Day 8</time_frame>
    <description>residual dosage of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Niraparib before Niraparib administration</measure>
    <time_frame>3 months</time_frame>
    <description>residual dosage of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>NIRAPARIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Niraparib Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Two different doses of Niraparib can be administrated:
For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.
For patient who had at baseline (T0) a body weight &lt; 77 kg or a platelet count &lt;150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.
Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.</description>
    <arm_group_label>NIRAPARIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients must be ≥ 18 years of age.

          -  Signed informed consent and ability to comply with treatment and follow-up.

          -  Patients with histologically proved high grade epithelial ovarian cancer or fallopian
             tube or primary peritoneal adenocarcioma.

          -  Platine sensitive and ovarian, fallopian or peritoneal cancer recurrent patients with
             a complete response or partial response after a line of platine based chemotherapy.

          -  Participant must have adequate organ function, defined as follows:

               -  Absolute neutrophil count ≥ 1,500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin ≥ 9 g/dL

               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine
                  clearance ≥ 30 mL/min using the Cockcroft-Gault equation

               -  Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR
                  direct bilirubin ≤ 1 x ULN

               -  Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver
                  metastases are present, in which case they must be ≤ 5 x ULN

          -  Patients with an indication of maintenance by Niraparib after platine based
             chemotherapy according to the labelling (labelling in process, see appendix 17).

          -  As this study will include patients in France, a subject will be eligible in this
             study only if either affiliated to, or a beneficiary of, a social category.

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of ≤ 2.

          -  Participant receiving corticosteroids may continue as long as their dose is stable for
             least 4 weeks prior to initiating protocol therapy.

          -  Participant must agree to not donate blood during the study or for 90 days after the
             last dose of Niraparib.

          -  Female participant has a negative urine or serum pregnancy test within 7 days prior to
             taking study treatment if of childbearing potential and agrees to abstain from
             activities that could result in pregnancy from screening through 1 month after the
             last dose of study treatment, or is of nonchildbearing potential.

          -  Participant must agree to not breastfeed during the study or for 1 month after the
             last dose of Niraparib.

        Exclusion Criteria:

          -  Known hypersensitivity or allergy to active principle or to any components or
             excipients of the Niraparib formulation.

          -  Participant must not be simultaneously enrolled in any interventional clinical trial.

          -  Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol
             therapy and participant must have recovered from any surgical effects.

          -  Participant must not have received investigational therapy ≤ 4 weeks, or within a time
             interval less than at least 5 half-lives of the investigational agent, whichever is
             shorter, prior initiating protocol therapy.

          -  Participant last treatment with platinum-based chemotherapy was ≥ 12 weeks from
             initiation of protocol therapy

          -  Participant has had radiation therapy encompassing &gt;20% of the bone marrow within 2
             weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy. - -
             - - -

          -  Participant must not have received a transfusion (platelets or red blood cells) ≤ 4
             weeks prior to initiating protocol therapy.

          -  Participant must not have received colony stimulating factors (e.g., granulocyte
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.

          -  Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due
             to prior chemotherapy that persisted &gt; 4 weeks and was related to the most recent
             treatment.

          -  Participant must not have any known history of myelodysplastic syndrome (MDS) or acute
             myeloid leukemia (AML).

          -  Participant must not have a serious, uncontrolled medical disorder, nonmalignant
             systemic disease, or active, uncontrolled infection. Examples include, but are not
             limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial
             infarction, uncontrolled major seizure disorder, unstable spinal cord compression,
             superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining
             informed consent.

          -  Participant must not be deprived of liberty, under guardianship or under trusteeship.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse 3, avenue du Général Harris 14076 CAEN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sidonie ADAM</last_name>
    <phone>+33(1)84852018</phone>
    <email>sadam@arcagy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sainte-Catherine Institut du Cancer Avignon-Provence</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GRENIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GRELLETY</last_name>
      <phone>0643439488</phone>
      <email>thomas.grellety@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa KALBACHER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine GARBAY-DECOOPMAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille CHAKIBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Fleyriat</name>
      <address>
        <city>Bourg-en-bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert ORFEUVRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel BRACHET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Maurice Tubiana</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel SEVIN</last_name>
      <phone>02 31 52 20 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medipole de Savoie</name>
      <address>
        <city>Challes-les-Eaux</city>
        <zip>73190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique MILLE</last_name>
      <phone>0678104147</phone>
      <email>dominik1000@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SASU Centre d'Oncologie et Radiothérapie 37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre COMBE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Ange MOURET-REYNIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure FAVIER</last_name>
      <phone>03 80 73 75 28</phone>
      <email>lfavier@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire GARNIER-TIXIDRE</last_name>
      <phone>04 76 28 52 32</phone>
      <email>c.garnier-tixidre@ghm-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle RAY-COQUARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olfa DERBEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mont-de-Marsan</name>
      <address>
        <city>Mont-de-marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela PETRAN</last_name>
    </contact>
    <contact_backup>
      <email>daniela.petran@ch-mdm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel FABBRO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SPAETH</last_name>
      <phone>03 83 93 50 05</phone>
      <email>d.spaeth@oncog.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe FOLLANA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre ONCOGARD - Institut de Cancérologie du Gard</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LEGOUFFE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme MEUNIER</last_name>
      <email>jerome.meunier@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme ALEXANDRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses-Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric SELLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire HARDY-BESSARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia RABAN</last_name>
      <email>nadia.raban@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Briac LEVACHE</last_name>
      <phone>05 53 02 13 32</phone>
      <email>ch.levache@oncoradio24.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karinne PRULHIERE-CORVIOLE</last_name>
      <email>kprulhiere@iccreims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude-Marie SAVOYE</last_name>
      <phone>03 26 50 43 97</phone>
      <email>aude-marie.savoye@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Malo</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine LE ROUX</last_name>
      <phone>02 99 21 21 50</phone>
      <email>d.leroux@ch-stmalo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DELECROIX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier COLLARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Emmanuel KURTZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - ONCOSUD</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond DESPAX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda FERNANDEZ DIEZ</last_name>
      <phone>0383598564</phone>
      <email>y.fernandez@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Anti-PARP (poly-ADP ribose polymerase)</keyword>
  <keyword>Late Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

